Study:
A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)
Rationale:
n/a
Purpose:
The primary purpose of the clinical research study is to assess the safety of treating
children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will
assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid
Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence
of disease flare.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Juvenile Rheumatoid Arthritis |
Drug: Abatacept
Drug: Placebo
Drug: Abatacept |
Phase 3 |
Verified by
Bristol-Myers Squibb
September, 2011
Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov identifier: NCT00095173
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Bristol-Myers Squibb., Study Director